Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Announces Third Quarter 2011 Financial Results
Nov 10, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2011 . Total revenue was approximately $0.2 million for the third quarter of 2011, compared with approximately $0.2
Aradigm to Present at the 10th Annual BIO Investor Forum on October 26
Oct 20, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda , Ph.D., will present at the 2011 Annual BIO Investor Forum on Wednesday, October 26, 2011 , at 11:00 a.m. Pacific time .
Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress
Sep 21, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (" Aradigm ") today announced it is presenting data on September 26, 2011 , from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands . The two podium presentations review the results from the Company's two
Aradigm to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 07, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Igor Gonda , PhD., Aradigm's President and CEO, will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011 at 4:05 pm Eastern time .
Aradigm Announces Second Quarter 2011 Financial Results
Aug 09, 2011
Two Key Transactions Strengthen Balance Sheet - Company Completes $8.5M Royalty Financing and Raises $4.75M in PIPE HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2011 .
Aradigm Announces Private Placement for $4.75 Million
Jul 06, 2011
Proceeds Will Further Development of Inhaled Liposomal Ciprofloxacin for the Treatment of Severe Respiratory Diseases HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it has entered into a definitive agreement for the sale of common stock to
Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
Jun 22, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it has entered into an $8.5 million royalty financing agreement (the "Transaction") with a syndicate of lenders arranged by PBS Capital Management LLC ("PBS Capital").
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
Jun 16, 2011
Both ARD-3100 Doses Met Primary Endpoint 2 mL Dose Found Equipotent to 3 mL Dose, with Excellent Safety and Tolerability HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced positive top line data from its recently concluded Phase 2b study ( O
Aradigm Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation in Bronchiectasis
Jun 06, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).
Aradigm Announces First Quarter 2011 Financial Results
May 12, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2011 . Total revenue was $0.2 million for the first quarter of 2011, compared with $4.0 million in revenue for the first
Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference
May 03, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that David Cipolla , M.S., Aradigm's Senior Director of Pharmaceutical Sciences, will present in an invited presentation in a plenary session at the Respiratory Drug Delivery Europe 2011 Conference
Aradigm Announces Fourth Quarter 2010 and Full Year Financial Results
Mar 24, 2011
Net Loss is Reduced by 61% While Advancing Bronchiectasis Clinical Studies HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2010 .
Aradigm Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis
Mar 22, 2011
Results Will Refine Protocols for Pivotal Phase 3 Trial Design HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with
Aradigm to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
Mar 10, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Igor Gonda , PhD., Aradigm's President and CEO, will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 4:00 pm Pacific time .
Aradigm to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
Feb 10, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 13 th Annual BIO CEO & Investor Conference on Monday, February 14, 2011 , at 3:00 p.m.
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
Jan 11, 2011
Aradigm to Earn 3% Royalty on Net Sales HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Zogenix, Inc. ("Zogenix", Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application
Aradigm to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis Study at Biotech Showcase 2011
Jan 06, 2011
Primary Endpoint — Reduction in Bacterial Load - Met Statistically Significant Secondary Endpoints of Delay to First Exacerbation and Reduction in the Need for Other Antibiotics HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and
SUMAVEL DosePro is Granted First European Approval
Dec 07, 2010
Aradigm to Earn 3% Royalty on Net Sales HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Zogenix, Inc. ("Zogenix", Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application
Aradigm Announces Third Quarter 2010 Financial Results
Nov 11, 2010
Company Eliminates $9.1M in Debt with Completion of Debt for Equity Transaction and Announces Awards of Over $733,000 in Government Grants HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months
Aradigm Appoints Tamar Howson to Board of Directors
Nov 04, 2010
Well-Known Industry Expert Strengthens Business Development Focus HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it appointed Tamar D. Howson to its board of directors. Ms. Howson brings significant business development and life sciences
Displaying 101 - 120 of 233
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.